3-8-dihydroxy-6h-dibenzo(b-d)pyran-6-one and Carcinoma--Hepatocellular

3-8-dihydroxy-6h-dibenzo(b-d)pyran-6-one has been researched along with Carcinoma--Hepatocellular* in 2 studies

Other Studies

2 other study(ies) available for 3-8-dihydroxy-6h-dibenzo(b-d)pyran-6-one and Carcinoma--Hepatocellular

ArticleYear
Antiproliferative effect of urolithin A, the ellagic acid-derived colonic metabolite, on hepatocellular carcinoma HepG2.2.15 cells by targeting Lin28a/let-7a axis.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2018, Volume: 51, Issue:7

    An abnormality in the Lin28/let-7a axis is relevant to the progression of hepatitis B virus (HBV)-positive hepatocellular carcinoma (HCC), which could be a novel therapeutic target for this malignant tumor. The present study aimed to investigate the antiproliferative and anti-invasive effects of urolithin A in a stable full-length HBV gene integrated cell line HepG2.2.15 using CCK-8 and transwell assays. The RNA and protein expressions of targets were assessed by quantitative PCR and western blot, respectively. Results revealed that urolithin A induced cytotoxicity in HepG2.2.15 cells, which was accompanied by the cleavage of caspase-3 protein and down-regulation of Bcl-2/Bax ratio. Moreover, urolithin A suppressed the protein expressions of Sp-1, Lin28a, and Zcchc11, and elevated the expression of microRNA let-7a. Importantly, urolithin A also regulated the Lin28a/let-7a axis in transient HBx-transfected HCC HepG2 cells. Furthermore, urolithin A decelerated the HepG2.2.15 cell invasion, which was involved in suppressing the let-7a downstream factors HMGA2 and K-ras. These findings indicated that urolithin A exerted the antiproliferative effect by regulating the Lin28a/let-7a axis and may be a potential supplement for HBV-infected HCC therapy.

    Topics: Analysis of Variance; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Coumarins; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Real-Time Polymerase Chain Reaction; Reference Values; Reproducibility of Results; RNA-Binding Proteins; Sincalide; Time Factors; Virus Replication

2018
In vitro antiproliferative and antioxidant effects of urolithin A, the colonic metabolite of ellagic acid, on hepatocellular carcinomas HepG2 cells.
    Toxicology in vitro : an international journal published in association with BIBRA, 2015, Volume: 29, Issue:5

    The intestinal metabolites of ellagic acid (EA), urolithins are known to effectively inhibit cancer cell proliferation. This study investigates antiproliferative and antioxidant effects of urolithin A (UA) on cell survival of the HepG2 hepatic carcinomas cell line. The antiproliferative effects of UA (0-500 μM) on HepG2 cells were determined using a CCK assay following 12-36 h exposure. Effects on β-catenin and other factors of expression were assessed by using real-time PCR and Western blot. We found that UA showed potent antiproliferative activity on HepG2 cells. When cell death was induced by UA, it was found that the expression of β-catenin, c-Myc and Cyclin D1 were decreased and TCF/LEF transcriptional activation was notably down-regulated. UA also increased protein expression of p53, p38-MAPK and caspase-3, but suppressed expression of NF-κB p65 and other inflammatory mediators. Furthermore, the antioxidant assay afforded by UA and EA treatments was associated with decreases in intracellular ROS levels, and increases in intracellular SOD and GSH-Px activity. These results suggested that UA could inhibit cell proliferation and reduce oxidative stress status in liver cancer, thus acting as a viably effective constituent for HCC prevention and treatment.

    Topics: Antineoplastic Agents; Antioxidants; Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Proliferation; Colon; Coumarins; Ellagic Acid; Hep G2 Cells; Humans; Liver Neoplasms; NF-kappa B; Oxidative Stress; Reactive Oxygen Species; Signal Transduction; Tumor Suppressor Protein p53

2015